Pediatric sleep disorders are common and are associated with significant behavioral and medical morbidity. Pediatric insomnia is the most prevalent pediatric sleep disorder and a frequent complaint in primary care settings. The recognized need for early detection and treatment of pediatric insomnia has prompted a proliferation of research supporting the efficacy of behavioral sleep treatments. However, there are few large-scale studies that have examined insomnia evaluation and treatment in real-world settings. Recently published treatment protocols provide increased clarity about the clinical delivery of evidenced based treatments. Despite advances in the field, there remain gaps in the translation of research findings to practice settings that have practical implications for clinical care. An overarching objective of this article is to demonstrate the feasibility of providing evidence based evaluation and treatment to children clinically referred for insomnia. We report a comprehensive data-driven analysis of the practice patterns and treatment outcomes from a well-established pediatric sleep medicine clinic. These findings expand the limited literature demonstrating the clinical effectiveness (vs. efficacy) of behavioral and cognitive behavior therapy for pediatric insomnia. Implications for practice and clinical effectiveness research are made based on the study findings.
2011; Meltzer, 2010) as well as a series of clinician-oriented protocols specifically targeting pediatric insomnia interventions (Perlis, Aloia, & Kuhn, 2011) . Each protocol provides a comprehensive description of the treatment including its theoretical basis, treatment rationale, indications/contraindications, and step-by-step guidelines for implementation (Didden, Sigafoos, & Lancioni, 2011; France, 2011; Kodak & Piazza, 2011; Meltzer & Mindell, 2011; Schnoes, 2011) . Despite these advances, there remain gaps in the translation of research findings to practice settings that have practical implications for clinical care. First, most treatment studies define sleep problems by symptoms and fail to group subjects according to etiology using diagnostic criteria (Mindell, Kuhn, Lewin, Meltzer, & Sadeh, 2006) . Consequently, there is insufficient evidence to support any single therapy over another for specific insomnia subtypes (Morgenthaler et al., 2006) . This researchpractice gap may undermine clinical treatment when optimal matching between a specific EST and specific patient is required. Second, there is a lack of clear-cut evidence to guide decisions about treatment frequency and duration of treatment interval. Furthermore, many extinctionbased treatment protocols recommend frequent clinician follow-up (e.g., daily phone calls) that may be unworkable in a high-volume clinical practice. Third, there is limited research examining insomnia treatment in school-age children and adolescents (Meltzer & Mindell, 2014) . A handful of studies have treated adolescents with adaptations of the empirically supported cognitive behavior therapy (CBT) model for adult insomnia (Bootzin & Stevens, 2005; Perfect & Elkins, 2010) . However, in pediatric settings, it is not clear at what age a CBT model for insomnia is indicated and what components of the model are most effective. Last, although there are a number of reliable and valid instruments that can be used for evaluating sleep in children and adolescents (e.g., sleep diaries; actigraphy), there is no "gold standard" for assessing insomnia severity in children. Furthermore, there are no widely used insomnia treatment outcome measures that can be reliably gathered at every treatment contact.
We are not aware of any published research that has systematically evaluated the clinical management of pediatric insomnia in a behavioral sleep medicine practice. Two prior studies describe clinical care in the context of a sleep disorders center (Meltzer, Moore, & Mindell, 2008; Stores & Wiggs, 1998) . However, neither study focused specifically on pediatric insomnia nor did they report outcomes supporting clinical effectiveness of behavioral sleep medicine interventions. This article reports the results of a comprehensive data-driven analysis of a wellestablished pediatric behavioral sleep medicine clinic. The overarching aim of the study is threefold: (a) demonstrate feasibility and clinical effectiveness of EST in a real-world setting, (b) glean insights and practical suggestions from our experience providing clinical care, and (c) integrate our findings with the most recent evidence supporting ESTs to guide clinical practice and clinical effectiveness research. Our specific aims were as follows: (a) characterize a large clinically referred sample of pediatric insomnia patients according to diagnostic etiology of insomnia and a range of clinically relevant variables (referral and triage parameters; sociodemographic variables; historical medical and mental health conditions; pretreatment screening using validated sleep measures); (b) describe treatment modalities used with a broad age range of pediatric patients; and (c) report treatment outcomes using a clinically validated treatment outcome measure and describe the course of treatment for children and adolescents with insomnia.
Method Patients
Patients and their caregiver(s) were seen at an accredited sleep disorders center from June 2009 through December 2012. Inclusion criteria were age Յ 18 years and a primary diagnosis of insomnia. Patients were enrolled at their evaluation following clinical referral. During the enrollment period, 527 patients were eligible for participation. Six parents did not provide consent and 12 families had incomplete data resulting in a final sample of 509 subjects (97% of eligible subjects). Patients were relatively evenly divided by sex and spanned the age range for inclusion in the study. The sample was broadly representative of the racial and ethnic make-up of the Greater Cincinnati metropolitan area. The majority of parents had at least some college or postsecondary education and the sample covered broad socioeconomic strata (see Table 1 ).
Procedures
The study site was a pulmonary-based accredited sleep disorders center (SDC) located in a tertiary care pediatric hospital and staffed by board certified sleep physicians and a licensed psychologist certified in behavioral sleep medicine. Insomnia evaluation and treatment were provided in the Behavioral Sleep Medicine Clinic (BSMC) by the psychologist or a psychology trainee under direct supervision. Patients referred to the SDC were triaged based on referral question and parent reported history gathered during an intake telephone interview. Patients with a chief complaint of insomnia without symptoms suggestive of an organic sleep disorder were triaged only to the BSMC. Patients with a chief complaint of insomnia and symptoms concerning for an organic sleep disorder were triaged to a board certified sleep physician and the BSMC. For patients with comorbid sleep disorders, active clinical collaboration with the attending sleep physician was the standard of care. All primary caregivers and each patient Ն 11 years of age completed pretreatment screening measures as part of routine clinical care. During a 90-min initial consultation, a comprehensive sleep evaluation and detailed treatment planning were completed.
Patients were diagnosed according to International Classification of Sleep Disorders Diagnostic and Coding Manual, 2nd edition criteria (ICSD-2; American Academy of Sleep Medicine, 2005) . The diagnostic nosology is reflective of the heterogeneity of insomnia in children and assigns diagnoses within an etiologic framework. Insomnia diagnoses include Behavioral Insomnia of Childhood (BIC) that represents the most prevalent diagnosis in young children. BIC subtypes (sleep association, limitsetting, combined) are defined by specific behavioral etiologies (Meltzer, 2010) . Psychophysiological insomnia, less prevalent in children, is characterized by a heterogeneous etiology and does not confer a clear-cut behavioral cause. Adjustment insomnia is short-lived and associated with a specific stressor. Inadequate sleep hygiene characterizes the patient with insomnia who routinely engages in behaviors that are incompatible with sleep.
After integration of all clinical data, families were provided evidenced-based treatment recommendations. The time-limited parent-guided therapies (e.g., graduated extinction) provided have been described extensively in the pediatric literature. The CBT approach used with preadolescents and adolescents was guided by the well-established CBT model for adults (Perlis, Jungquist, Smith, & Posner, 2005) . When more than one treatment modality was indicated (e.g., unmodified extinction vs. graduated extinction for sleep onset association disorder), family and patient factors (e.g., parenting philosophy; child temperament) were carefully considered when making final treatment decisions. Following discussion of the child's diagnosis, treatment rationale, and treatment selection, parents were given a written version of the treatment plan and relevant supports (e.g., sleep diaries, sticker charts). When formal follow-up was recommended, the time-frame was agreed upon and parents were given scheduling information. The Institutional Review Board provided oversight for the study. Eligible families received print and verbal information explaining that the purpose of the study was to archive de-identified clinical information for clinical research. Primary caregivers provided written informed consent before being enrolled in the study.
Clinical Measures
The Sleep Disorders Center History Questionnaire (SDCHQ) is a parent report measure developed by the SDC to obtain relevant history and demographic information via open ended questions, multiple choice format for demographic information, and yes/no responses regarding history of relevant health conditions. For the purposes of this study the SDCHQ was used to gather demographic variables and patient medical and mental health history. The Children's Sleep Habits Questionnaire (CSHQ) is a 33-item parent-report measure of sleep behavior and sleep disorders symptoms (Owens, Spirito, & McGuinn, 2000) . Caregivers use a 3-point Likert scale to rate the frequency of specific sleep symptoms/behaviors during the previous week (rarely to usually). The measure yields a total score and eight subscale scores for which higher scores represent more problematic sleep. The CSHQ has demonstrated validity for use with preschool and school-age children and has been shown to differentiate clinical from control groups (Goodlin-Jones, Sitnick, Tang, Liu, & Anders, 2008; Owens et al., 2000) . Published psychometrics demonstrate adequate internal consistency (.68 -.78) and test-retest reliability (.62-.79); subscale reference values for clinical and community comparison groups are available. Prior research has demonstrated use of subscale clinical cut-off values (2 SD Ͼ mean for reference controls) to identify clinically significant problems (Byars, Apiwattanasawee, Leejakpai, Tangchityongsiva, & Simakajornboom, 2011) . A total score Ͼ 41 on the CSHQ has been identified as the most sensitive clinical cut-off for identifying sleep problems in children (Owens et al., 2000) .
The Adolescent Sleep Wake Scale (ASWS) is a 33-item self-report measure that assesses sleep quality in adolescents (LeBourgeois, Giannotti, Cortesi, Wolfson, & Harsh, 2005) . Respondents report frequency of sleep behaviors during the past month using a 6-point scale (always to never). Sleep is measured along five behavioral dimensions. Mean subscale scores and a fullscale sleep quality score are computed. Scores range from 1-6, with higher scores indicating better sleep quality. Psychometrics for the ASWS demonstrate adequate reliability for the subscales (␣ ϭ .60 -.82) and full scale (␣ ϭ .80 -.86) as well as concurrent validity through associations with the Adolescent Sleep Habits Scale (LeBourgeois et al., 2005) . Independent peer review of the ASWS supports its use as a measure of sleep quality (Lewandowski, Toliver-Sokol, & Palermo, 2011) . In our clinical practice the ASWS is used as a screening tool to identify problem areas for further assessment. Previously published control and clinical group scores are used as reference values (LeBourgeois et al., 2005; Palermo, Fonareva, & Janosy, 2008) . Our anecdotal experience is that subscale scores Ͻ 4 align with areas targeted for clinical treatment. Because there are no published norms for the ASWS, for purposes of this study we used scores Ͻ 4 on the ASWS subscales to identify clinically relevant problems.
The Pediatric Insomnia Severity Index (PISI) is a 6-item paper-pencil measure developed by our center to monitor pediatric insomnia treatment outcomes within the context of clinical care. The PISI assesses sleep domains most relevant to clinical treatment: sleep onset problems (two items), sleep maintenance problems (two items), daytime sleepiness (one item), and nocturnal sleep duration (one item). Scores range from 0 to 30, with higher scores indicative of more severe insomnia. For children Յ 10 years of age, the PISI-Child (PISI-C) is completed by a primary caregiver; patients 11-to 18-years-old complete the self-report PISIAdolescent (PISI-A). The total nocturnal sleep item is rated on a 0 -6 point scale with each rating designating an estimate of total hours slept on most nights (e.g., 6 ϭ less than 5 hr of sleep). All other items are rated on a 0 -6 point scale from never (0 times per week) to always (7 nights per week). Respondents are asked to characterize the patient's sleep over the prior week. The PISI was completed at the initial evaluation and at all follow-up clinic visits. Over the past 4.5 years since implementation of the PISI in our clinic, clinicians have consistently collected the measure at almost every (Ͼ97% of visits) treatment contact. Validity and reliability data on PISI have not been published elsewhere. Pearson correlation between baseline PISI-C and CSHQ total scores (r ϭ .369; p ϭ .000) and baseline PISI-A and ASWS total scores (r ϭ Ϫ.418; p ϭ .000) demonstrate acceptable validity (Cohen, 1988; Hemphill, 2003) . Adequate reliability of the PISI is demonstrated by high internal consistency for the entire PISI-C and PISI-A scales (Cronbach's alpha ϭ .79 and .80, respectively) as well as the item subsets measuring sleep onset problems (.92 to .94) and sleep maintenance problems (.72 to .73).
Data Analytic Plan
SPSS Statistics software, version 22 was used for data analysis. Data preprocessing included computing subscale and/or total scores for the CSHQ, ASWS, and PISI. On the CSHQ and ASWS, missing data were typically the result of the omission of one or two items on a multiitem subscale. In cases where less than 50% of subscales items were missing, composites were prorated from the remaining items for the subscale (Beebe et al., 2007) . If more than 50% of the item level responses making up a subscale were missing, all data for that case were eliminated from final data analysis. In cases where the PISI was missing or incomplete, all data for that case were eliminated from final data analysis. When demographic data were incomplete, the number of cases for missing data is reported.
Descriptive statistics for relevant study variables, total scores for all sleep measures, and frequencies for clinically significant pretreatment scores on screening measures are reported. Prepost treatment scores on the PISI were compared using t tests. Treatment outcomes and course of treatment parameters for measures are reported. Pre/post treatment scores on the PISI were compared using t tests. Treatment outcomes and course of treatment parameters for patients that formally terminated treatment versus patient that terminated early were analyzed and reported. All statistical tests were evaluated at the p Ͻ .05 significance level and constituted two-tailed tests.
Results

Referral and Triage Patterns
Of the 509 referrals, most (n ϭ 297) were received from external referral sources, predominantly primary care providers (78%) and self-referrals (20%). Within the institution referrals (n ϭ 212) were received most often from the divisions of pulmonary medicine (31%), behavioral pediatrics (20%), neurology (16%), and psychiatry (13%). Slightly over one third of the referrals (n ϭ 159) were direct referrals to the division of psychology for the sleep psychologist, and most of the referrals (n ϭ 350) were direct referrals to the SDC. Of the direct referrals to the SDC, just over half (n ϭ 192) were triaged only to the BSMC and the remainder (n ϭ 152) were triaged to both the sleep psychologist and one of the attending sleep physicians.
Insomnia and Comorbid Sleep Disorder Diagnoses
Nearly 70% of the sample was diagnosed with BIC; the most common subtype was sleeponset association, followed by combined type, and limit-setting type. One third of the patients were diagnosed with psychophysiological insomnia. Twenty-eight percent (n ϭ 144) of the patients had one or more comorbid sleep diagnosis made by a board certified sleep physician. Diagnoses included sleep-related breathing disorders, parasomnias, and sleep-related movement disorders. The most common comorbid diagnosis was primary snoring (20.8%). Other common diagnoses included sleep terrors, nightmares, sleepwalking, obstructive sleep apnea, and nocturnal enuresis. Sleep related movement disorders were rare (see Table 2 ).
Relevant Medical History
Parents endorsed medical histories positive for a number of health conditions that may be disruptive to a child's sleep. Over 20%-30% of the sample had reported histories of environmental allergies (n ϭ 176), eczema (n ϭ 148), developmental delay (n ϭ 144), headaches (n ϭ 126), heartburn (n ϭ 125), and asthma (n ϭ 111). Less than 10% of the sample endorsed a history of seizures (n ϭ 49) and craniofacial disorders (n ϭ 9).
Mental Health History
Over half of the patient sample (n ϭ 263) had at least one historical mental health diagnosis. Anxiety disorders as a group were common (33%); specific diagnoses included generalized anxiety disorder (n ϭ 98), anxiety disorder-NOS (n ϭ 57), obsessive-compulsive disorder (n ϭ 8), and posttraumatic stress disorder (n ϭ 3). Attention deficit hyperactivity disorder (n ϭ 125) had at prevalence of 25% in the sample. Mood disorders were much less common (7%) and included depression (n ϭ 28), bipolar disorder (n ϭ 7), and mood disorder-NOS (n ϭ 2). Autism Spectrum Disorders were endorsed in less than five percent of the sample and included autism (n ϭ 15), Asperger disorder (n ϭ 6), and pervasive developmental disorder-NOS (n ϭ 1).
Pretreatment Sleep Screening Measures
CSHQ and ASWS scores and the prevalence of clinically significant problems based on clinical cut-off scores on these measures are summarized in Table 3 . Essentially all children had a CSHQ total score indicative of a clinically significant sleep problem. Cut-off scores on the CSHQ and ASWS identified problem areas across all subscale domains. In younger children, insufficient sleep and night wakings were most prevalent. In the preteens and adolescents, falling asleep and waking in the morning were most frequently endorsed as clinically significant problems.
Treatment Modalities
The behavioral therapies and CBT used in our clinic are summarized by diagnosis in Table 4 . Adjustment insomnia and inadequate sleep hygiene were primary sleep diagnoses representing less than 1% of the sample and therefore were not included in the table. Because describing specific treatment procedures for the ESTs is beyond the scope of this article, citations for descriptions of the treatment modalities used are provided in a footnote to Table 4 .
Treatment modalities varied according to diagnosis with graduated extinction and extinction with parent presence being used most often with BIC-sleep onset association type, while positive routines, faded bedtime, and the bedtime pass were more often used to treat BIClimit-setting type and BIC-combined type. Multicomponent CBT for insomnia and CBT components (stimulus control therapy, sleep restriction, cognitive restructuring, relaxation training) were most often used with patients diagnosed with psychophysiological insomnia. Small to medium effects (Cohen, 1988) were observed for correlations between younger patient age (mean age Յ 6 years old per treatment group) and behavioral treatment modalities that are parent guided: unmodified extinction, extinction with parent presence, graduated extinction, and positive routines (range of r ϭ Ϫ117 to Ϫ.409; p Յ .008). Similar effect sizes were observed for correlations between older patient 3 CSHQ subscale cut-off is 2 SD Ͼ mean for community sample (Owens et al., 2000) . 4 CSHQ total clinical cut-off score of 41 (Owens et al., 2000) . 5 ASWS cut-off 4 based on our clinical experience and prior studies (LeBourgeois et al., 2005) . (Mindell, Kuhn, et al., 2006) . 4 (Friman et al., 1999) . 5 (Perlis et al., 2005) .
age (mean age Ն 11 years old per treatment group) and multicomponent CBT, sleep restriction, stimulus control therapy, cognitive restructuring, and relaxation training (range of r ϭ .178 to .522)
Insomnia Treatment Outcomes
Pre-and posttreatment scores for the PISI are presented in Table 5 . A flow diagram characterizing the patient subsamples is presented in Figure 1 . Clinic-based follow-up after the initial evaluation was recommended to most patients (453 out of 509) and approximately 49% of those patients returned for follow-up treatment The treatment group (n ϭ 220) included all patients that formally initiated treatment and were seen for Ն 1 follow-up treatment session. Treatment was formally terminated during a scheduled clinic visit when the treating clinician and family agreed that treatment goals were met. The treatment group was subdivided into two groups: (a) patients that initiated treatment but never formally terminated treatment (early termination group); and (b) patients that formally terminated treatment (formal termination group). Posttreatment PISI scores indicated that 80% of children and adolescents in the early termination group showed improvement in insomnia severity. Children and adolescents in the formal termination group showed improvement in insomnia severity of 90.2% and 88.9%, respectively. Irrespective of treatment group (early vs. formal termination), children and adolescents had statistically significant improvement in insomnia severity following treatment. The children that formally terminated treatment (51 of 157) had better outcomes based on statistically significant differences when compared with the early termination group on measures of insomnia severity, t(155) ϭ 2.456, p ϭ .015. There were also statistically significant differences between the formal and early termination groups with respect to course of treatment: mean treatment duration (days; 127.80 Ϯ 136.98 vs. 60.06 Ϯ 73.58), t(155) ϭ Ϫ4.032, p ϭ .000, and mean number of treatment sessions (3.47 Ϯ 2.30 vs. 2.75 Ϯ 1.24), t(155) ϭ Ϫ2.571, p ϭ .011. Approximately 29% (18 of 63) of the adolescents formally terminated treatment; trends for the adolescents were similar to that in children but were not statistically significant.
Discussion
Similar to the field of pediatric psychology as a whole, great advances have been made through treatment efficacy studies that are abundant for behavioral therapies targeting sleep disturbances in young children. However, there are few large-scale studies that have examined the clinical effectiveness of pediatric insomnia treatments in practice settings (Chambless & Hollon, 1998; Drotar, 2010; Kazdin, 2008; Mindell, Kuhn, et al., 2006) . In light of the challenges that often undermine clinical research in the context of active clinical care (e.g., focus on billing productivity; lack of extramural funding for applied research; Drotar, 2010), we set out over a decade ago to establish a data-driven, evidenced-based, and patient-centered practice. This study represents the culmination of trials and errors that yielded a clinical practice model that adheres to EST and places a priority on patient care needs. Our findings advance the clinical effectiveness literature for pediatric insomnia in the following important ways: (a) patient stratification by diagnostic etiology al- lowed treatment modalities to be assigned to patients according to a specific insomnia classification or subtype; (b) treatment outcomes are reported for a large clinically referred sample representing a broad age range including preadolescents and adolescents, an age group that has seemingly been overlooked with regards to nonpharmacological treatment for insomnia; (c) insights were gained regarding decision-making about treatment frequency and duration in light of the study findings and our experience providing patient-centered care; (d) preliminary support for a novel pediatric insomnia treatment outcome measure is reported; and (e) the feasibility of establishing and maintaining a clinical research repository within the context of a high volume clinical practice is demonstrated.
Clinical Effectiveness Outcomes
The study findings show that behavior therapy and CBT for insomnia reduced insomnia severity in a large sample of clinically referred patients. Moreover, the clinical significance of improved insomnia severity scores is validated in some measure through anecdotal observations of parent satisfaction with treatment. Treatment modality varied according to ICSD-2 diagnosis and patient age. Younger patients with BIC typically received parent guided interventions that were often extinction-based treatments. Older patients, including adolescents, with psychophysiological insomnia responded to CBT. Although, treatment duration and frequency of sessions varied, in most cases treatment spanned no longer than 12 weeks and required no more than four sessions. Formal follow-up was recommended for most patients, but less than half were seen for follow-up. The one third of the treatment patients who formally terminated treatment demonstrated a better treatment response than patients that terminated early. Posttreatment outcome scores indicate younger children had a better treatment response than preadolescents and adolescents.
Research Embedded in Care
The greatest catalyst for our work with respect to data collection, analysis, and dissemination was institutional and divisional support to create an IRB-approved research repository for tracking clinical practice patterns and treatment outcomes. Clinical data are archived electronically through the use of TeleForm® documents (http://www.autonomy.com/products/ teleform) at the outset of care and are used in real-time to answer clinically relevant research questions. Patients consent to have their clinical data deidentified and stored for clinical research purposes. Establishing a clinical research repository has led to the ability to conduct analyses of clinical data in real time that was not possible when clinical data was archived in paper med- ical records or on research coding forms. Periodic review of clinical outcomes and practice patterns for the program helps to inform treatment and practice management decisions in tangible ways. For example, families generally show appreciation about information shared from the clinical repository (e.g., "our work with families tells us that the sleep of most patients improves within about 6 weeks of starting treatment, sometimes sooner, and if families return for follow-up services they usually require no more than 1-3 additional visits").
Limitations
There are some limitations of this study. First, although reliance on patient and parentreport is common practice in the clinical setting, rater bias cannot be ruled out for subjective reports on study measures. Second, although treatment was provided according to EST protocols with a focus on optimizing participant understanding and adherence, the need for flexibility in the clinical setting precluded strict compliance to manualized treatment. Also related to treatment fidelity is the lack of formal assessment of treatment receipt according to strict criteria (Gearing et al., 2011) . Third, because the PISI is a novel measurement tool, its use as the sole outcome measure in our study could be viewed as a study limitation. Lastly, it is not uncommon for us to work with patients that have been prescribed or are currently taking over-the-counter and/or prescription medication for insomnia. Our experience is consistent with a national trend toward increased use of medication to treat pediatric insomnia despite a lack of efficacy data (Mindell, Emslie, et al., 2006; Owens, Rosen, & Mindell, 2003) . The use of medication for insomnia was not systematically assessed in our sample.
Clinical Implications and Future Directions
Undoubtedly, long-term follow-up is required to demonstrate maintenance of treatment gains overtime; however, when providing timelimited insomnia treatment, the benefits of therapy may go unrecognized in cases lost to follow-up in the short-term. Alternatively, the factors that lead to premature termination of treatment may never be appreciated. In our sample, a majority of the patients never returned to clinic despite specific recommendations for follow-up that were part of the treatment plan. Better understanding the circumstances that lead to early treatment withdrawal and the factors associated with treatment limited to a single patient encounter could dramatically change service delivery. The implications for both clinician (e.g., decreased no-show rates) and patient (e.g., access to a psychologist when needed) are quite pronounced. In light of the limited evidence to guide decisions about the need and timing of short-term clinic follow-up, systematic collection of treatment outcomes after a single treatment session could mitigate problems such as no-shows, unneeded follow-up appointments, and early treatment complications that might lead to premature termination of services. Accordingly, further validation of the PISI and consideration of its use via nontraditional follow-up mechanisms (e.g., telepsychology; electronic communication) is warranted.
Insomnia is prevalent throughout childhood and adolescence (Owens, 2005) , yet the bulk of treatment research has focused on children under the age of 5 years (Meltzer & Mindell, 2014) . Although the magnitude of treatment effects was smaller when compared with younger children, data from this study provide support for the clinical effectiveness of behavioral therapy and CBT for insomnia in preadolescents and adolescents. This evidence is reassuring and at the same time underscores the recognized need to develop insomnia treatments that are more specific to the clinical needs of older children and adolescents (Meltzer & Mindell, 2014) .
Lastly, there are financial concerns that may complicate day-to-day operations within clinical practice and may discourage some practitioners from engaging in behavioral sleep medicine services. Although insurance reimbursement for services has improved for the field of clinical sleep medicine as a whole (Shepard et al., 2005) , payment for behavioral sleep medicine services seems to have lagged behind (McCrae, Taylor, Smith, & Perlis, 2010; Pigeon, Crabtree, & Scherer, 2007) . This is exemplified in clinical settings where state-of-the-art evidenced-based care is provided, yet psychologists do not bill because insurance contracts do not recognize sleep treatment provided by a psychologist as a covered benefit (Meltzer et al., 2008) . There is a need to gather regional and national data regarding re-imbursement for behavioral sleep medicine services and to disseminate such to the relevant clinical psychologist constituencies. In addition, psychologists should lobby their state and national organizations to educate commercial payors regarding the important role that psychologist play in the care of children with acute and chronic health conditions including pediatric sleep disorders. More specifically, there is need for further dissemination of administrative and billing guidelines for use in the psychological care of children with sleep disorders including insomnia.
